Podcasts about systems pharmacology

Today, we are honored to have Dr. E. John Wherry, a leading expert in the field of immunology, joining us. Dr. Wherry is the Chair of the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania, where he also directs the Institute for Immunology. His undergraduate degree was obtained at Penn State University before completing his PhD in Immunology at the Thomas Jefferson University. A thought leader in T cell biology and immune memory, Dr. Wherry's work has been instrumental in improving therapies for viral infections, vaccines, and immunotherapy treatments. His discoveries in the field of immune exhaustion have had a profound impact on the way we approach treatments for cancer and autoimmune diseases. Widely published in top academic journals including Nature, Cell, and Science, Dr. Wherry is a heavy contributor to Covid research and especially the understandings of long Covid. Today, we discuss Covid and the current state of the science regarding vaccines, long covid and what we can do better next time there is a pandemic. Enjoy, Dr. M  

In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th birthday, Professor Rostami will provide insights into his journey, the dynamic evolution of PBPK and QSP, and the exciting horizons ahead. Tune in for a deep dive into the intersections of academia and industry, technological advancements, and the invaluable lessons garnered throughout a pioneering career.The episode explores the following:The key milestones and highlights of Professor Amin's career in PBPK and QSPThe factors that initially captivated his interest in PBPK, and how the field evolved over the decades of his careerThe role of translational and systems pharmacology in shaping the future of drug developmentBalancing between academic and industry rolesAdvice to young scientists and researchers entering the field of PBPKSpeaker:Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX, FBPS – Professor of Systems Pharmacology & Director of Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK. SVP of R&D, Chief Scientific Officer (CSO), Certara, Princeton, USA The work of Professor Rostami covers wide areas of drug development over the last 30 years, ranging from pharmaceutics (e.g. bioavailability and bioequivalence) to clinical pharmacology (e.g. mixture pharmacology of drug/metabolites), translational and systems pharmacology (e.g. quantitative proteomics of enzymes and transporter for in vitro to in vivo (IVIVE) scaling). As the Director of Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester, Amin collaborates with many pharmaceutical companies with a view to transfer latest scientific applications into modern drug development.  Amin was co-founder of two spin-off companies from the University of Sheffield (Simcyp Limited [now part of Certara Inc]) and Diurnal Limited [now part of Neurocrine Bioscience]). As a leader in the field of Physiologically-based Pharmacokinetics (PBPK) and Quantitative Systems Pharmacology (QSP), he is internationally recognized for his expertise in IVIVE to predict the behavior of drugs in human body and understanding the associated inter-individual variabilities. He was one of the founding editors of Pharmacometrics and System Pharmacology and serves on the Editorial Boards of several other journals. As the Senior Vice President of Research & Development (SVP) and Chief Scientific Officer at Certara, he facilitates the incorporation and integration of the latest advances in translational modelling to bio-simulation platforms offered by Certara to its clients, with the aim of accelerating the development and regulatory approval of safer drug products and bringing them to the patients.  Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

Why are T cells so vital to our immune response? As one of the primary markers of a potential issue, a problem with your T cells could spell disaster. Listen up to learn: The function of a T cell What T cells recognize How T cell exhaustion can be reversed Offer:Want a safe energy-boosting alternative to caffeine? Want to lower free radical damage so you can enjoy optimal cognition, faster muscle recovery, and exceptional wellness? Take the 30-day hydrogen challenge. Drink 2 glasses of hydrogen water daily for 30 days to zap the most damaging free radicals and unleash your inner energy.To get started, use code genius to save 20% on your first order from TryVitalReaction.com John Wherry, the Chair of the Department of Systems Pharmacology at the University of Pennsylvania, shares his research in epigenetics and the vital role of T cells in our immune system. T cell differentiation is an essential process in our body, initially being able to control infection and limit tumor growth. However, if the process reaches T cell exhaustion, it can cause a variety of problems in our immune response. While T cell exhaustion is similar to viruses and tumors, the response can be varied, even if slightly. Still, the reversal of T cell exhaustion has been shown to be effective and will only become more comprehensive as research progresses. Visit https://www.med.upenn.edu/wherrylab/ for more information. Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Dr Garret FitzGerald, professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine at the University of Pennsylvania joins me on the podcast today. Hailing from Wicklow, Garret is an international leader in cardiovascular disease research and leading world figure in pharmacology. He discusses his work into the development of low-dose aspirin for cardioprotection and his investigations into harmful effects and cardiovascular risks of NSAIDs. He also discusses the importance of the presence of molecular clocks in the cardiovascular system. We chat about his 'unusual' upbringing in the 'Grand Hotel' in Greystones, being an only child and the 'series of accidents' that have led to him becoming a physician scientist. We also discuss his move to London and subsequently the US and his hopes for the future of Irish science. Garret is also extremely passionate about bridging the gap between basic science and clinical impact and the importance of creating structures for career progression for younger researchers.    Follow Garret: FitzGerald__Lab Follow me: MeganHanlon4 This season is kindly sponsored by Bio-Sciences Ltd, now part of Thermo-Fisher Scientific.

Dr. Christina Gavegnano is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University. Dr. Gavegnano earned her PhD in Molecular and Systems Pharmacology from Emory University and has focused her research on the role of JAK inhibitors in the treatment of HIV. With the outbreak of the COVID pandemic, she refocused her efforts and, along with her collaborators, pioneered the use of baricitinib for the treatment of COVID-19. Today she shares her remarkable journey from bench to bedside in the midst of a global health crisis. Credits: Our deepest thanks to Dr. Gavegnano for being on the show! Dr. Gavegnano's faculty page: https://med.emory.edu/departments/pediatrics/divisions/biochem/profile/?u=CGAVEGN Follow Dr. Gavegnano on Twitter: @GavegnanoG. Host - Bejan Saeedi Co-Host and Audio Engineer – Joe Behnke Executive Producer and Social Media Coordinator – Carey Jansen Executive Producer – Michael Sayegh Faculty Advisor – Dr. Brian Robinson Twitter: @behindthescope_ Instagram: @behindthemicroscopepod Facebook: @behindthemicroscope1 Website: behindthemicroscope.com

Host Alaina Webster sits down with Dr. Jonathan French to discuss the best organizational practices for a review – both from an associated editor's standpoint and from an author's. Jonthan, an Associate Editor for CPT: Pharmacometrics & Systems Pharmacology, delves into why he appreciates reviews that are broken up into three sections as well as why ASCPT's journals ask for comments to the editor as well as the reviewer. You can access PSP's Reviewer Instructions and contact the editorial office to volunteer as a reviewer here.

In the fourth episode in the peer review series, Dr. Stefanie Hennig joins host Alaina Webster to walk you through what editors do with a review once it's received. Stefanie, an Associate Editor for CPT: Pharmacometrics & Systems Pharmacology details her first steps upon receiving a review, how much a reviewer's opinion influences her decision on a manuscript, and how she decides is reviewers are needed for a revised manuscript. You can access PSP's Reviewer Instructions and contact the editorial office to volunteer as a reviewer here.

FIRST (interview)! My friend Lynnea Harris joins me on the Sound in our first interview. We sing, we laugh, we discuss impulse buys (in the love of science).  We breakdown the 1963 heartbreak single "Put Me Down Easy" by Sam Cooke's little brother, L.C Cooke. We tie that song to Lynnea's research to how opioids work. More below about my guest, Lynnea Harris."Born and raised in Dallas, Texas. Lynnea Harris is a 5th year PhD student studying Molecular and Systems Pharmacology at Emory University under (the high-key famous) Dennis C. Liotta. Her thesis project focuses on opioid medications in rodents and attempts to find methods to inhibit the development of opioid tolerance."The Song of the Week: Free as the Wind  by The Crusaders---Follow UsInstagram @scientificallysound Twitter: 4theSci_SoundEmail : 4thescientificallysound@gmail.com 

On the latest episode of PSPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.

On the latest episode of ClinPharmPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.

On the latest episode of PSPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.

On the latest episode of ClinPharmPod, host Alaina Webster is joined by France Mentré, MD, PhD, Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology, Deanna L. Kroetz, PhD, Deputy Editor-in-Chief of Clinical and Translational Science, and Shirley K. Seo, PhD, Associate Editor of Clinical Pharmacology & Therapeutics, to discuss their experiences of how COVID-19 has affected submissions and peer review for the ASCPT Family of Journals. Brian Coughlin, Publisher at Wiley, serves as moderator for the discussion.

 In Episode 73, Quinn & Brian asked: Did A.I. take our jobs? Of course, we aren’t talking about our jobs. If A.I. took our jobs, the show would have won that goddamn Webby. No, no — we’re talking about really, really important jobs – the jobs being done by people like Dr. Mohammed AlQuraishi, who is a Department Fellow at the Laboratory of Systems Pharmacology and the Department of Systems Biology at Harvard Medical School. Still, Dr. AlQuraishi is hopeful about the future and his role in it — an attitude that was refreshing the first time we aired this episode and is downright necessary right now. Have feedback or questions? Tweet us (http://www.twitter.com/importantnotimp) , or send a message to funtalk@importantnotimportant.com Trump’s Book Club:  (https://www.amazon.com/registry/wishlist/3R5XF4WMZE0TV/ref=cm_sw_r_cp_ep_ws_2Gr8Ab6RS5WF3) by Steven Pinker Links: Learn more at https://moalquraishi.wordpress.com (https://moalquraishi.wordpress.com) Twitter: https://twitter.com/moalquraishi (https://twitter.com/moalquraishi) “The Future of Protein Science will not be Supervised” (https://moalquraishi.wordpress.com/2019/04/01/the-future-of-protein-science-will-not-be-supervised/) Chan Zuckerberg Initiative: chanzuckerberg.com (https://chanzuckerberg.com/) Connect with us: Subscribe to our newsletter at ImportantNotImportant.com (http://importantnotimportant.com/) ! Follow us on Twitter: twitter.com/ImportantNotImp (http://twitter.com/ImportantNotImp) Follow Quinn: twitter.com/quinnemmett (http://twitter.com/quinnemmett) Follow Brian: twitter.com/briancolbertken (http://twitter.com/briancolbertken) Like and share us on Facebook: facebook.com/ImportantNotImportant (http://facebook.com/ImportantNotImportant) Intro/outro by Tim Blane: timblane.com (http://timblane.com/) Important, Not Important is produced by (http://crate.media/) Support this podcast

An interview with Dr. Nichola Conlon about upregulating cellular NAD+

The safety and efficacy of therapeutic drugs still requires improvement. However, the advent of both systems biology and precision medicine has stimulated a rethink on the process of therapeutic drug design and polypharmacology. More recently, the definition of polypharmacology has morphed to represent therapeutic drugs that have been designed deliberately for multi-targeting that affords beneficial effects to the patient. This emerging effort has been labelled ‘Systems Pharmacology’ and the products are referred to as multi-target or systems pharmacology drugs. This episode is part 2 of 2 episodes and goes into more detail on systems pharmacology, going through definitions, combination therapy vs systems pharmacology drugs, implementation and approaches. Original article by Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor If you'd like to view the original article then follow the link below: https://www.ddw-online.com/therapeutics/p322783-perspective-on-systems-pharmacology:-when-multi-targeting-is-advantageous.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/135186/(4)-perspective-on-systems.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

The safety and efficacy of therapeutic drugs still requires improvement. However, the advent of both systems biology and precision medicine has stimulated a rethink on the process of therapeutic drug design and polypharmacology. More recently, the definition of polypharmacology has morphed to represent therapeutic drugs that have been designed deliberately for multi-targeting that affords beneficial effects to the patient. This emerging effort has been labelled ‘Systems Pharmacology’ and the products are referred to as multi-target or systems pharmacology drugs. This episode is part 1 of 2 episodes on the topic of systems pharmacology, and covers ­­human complexity, systems biology and precision medicine. Original article by Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor If you'd like to view the original article then follow the link below: https://www.ddw-online.com/therapeutics/p322783-perspective-on-systems-pharmacology:-when-multi-targeting-is-advantageous.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/135186/(4)-perspective-on-systems.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

In Episode 73, Quinn & Brian ask: Hold On A Minute -- Did A.I. Just Take Our Jobs?  Of course, we aren’t talking about our jobs. If A.I. took our jobs, the show would have won that Webby. We’re talking about really, really important jobs – like curing cancer and slowing down our climate collapse. But we are talking about people like our guest Dr. Mohammed AlQuraishi, who is a Department Fellow at the Laboratory of Systems Pharmacology and the Department of Systems Biology at Harvard Medical School. Still, Dr. AlQuraishi is hopeful about the future and his role in it – an attitude so refreshing it’s like stumbling onto a digital oasis in the internet’s hateful and pessimistic desert. Want to send us feedback? Tweet us, email us, or leave us a voice message! Trump’s Book Club: The Better Angels of Our Nature: Why Violence Has Declined by Steven Pinker: https://www.amazon.com/registry/wishlist/3R5XF4WMZE0TV/ref=cm_sw_r_cp_ep_ws_2Gr8Ab6RS5WF3 Links: Have feedback or questions? Send a message to funtalk@importantnotimportant.com Leave us a voice message: anchor.fm/important-not-important/message Learn more at https://moalquraishi.wordpress.com Twitter: https://twitter.com/moalquraishi “The Future of Protein Science will not be Supervised”: https://moalquraishi.wordpress.com/2019/04/01/the-future-of-protein-science-will-not-be-supervised/ Chan Zuckerberg Initiative: https://chanzuckerberg.com Connect with us: Subscribe to our newsletter at ImportantNotImportant.com! Check out our Morning Show and other daily bite-size content on Instagram: instagram.com/ImportantNotImportant Leave us a voice message: anchor.fm/important-not-important/message Follow Quinn: twitter.com/quinnemmett Follow Brian: twitter.com/briancolbertken Follow us on Twitter: twitter.com/ImportantNotImp Like and share us on Facebook: facebook.com/ImportantNotImportant Pin us on Pinterest: pinterest.com/ImportantNotImportant Tumble us or whatever the hell you do on Tumblr: importantnotimportant.tumblr.com Intro/outro by Tim Blane: timblane.com Important, Not Important is produced by Crate Media Support this podcast

On this episode of PSPod, Drs. Piet van der Graaf and Suruchi Bakshi from Certara QSP and Leiden University, and Dr. Chao Chen from Clinical Pharmacology Modelling & Simulation at  GlaxoSmithKline, discuss quantitative systems pharmacology (QSP) modeling in relation to the study of Parkinson’s disease. This discussion is based on a Review article that published in the February 2019 issue of PSP, which is available here.

On this episode of PSPod, Drs. Piet van der Graaf and Suruchi Bakshi from Certara QSP and Leiden University, and Dr. Chao Chen from Clinical Pharmacology Modelling & Simulation at  GlaxoSmithKline, discuss quantitative systems pharmacology (QSP) modeling in relation to the study of Parkinson’s disease. This discussion is based on a Review article that published in the February 2019 issue of PSP, which is available here.

On today’s episode, Dr. Paul Watkins, the Howard Q. Ferguson Distinguished Professor at Eshelman School of Pharmacy, University of North Carolina at Chapel Hill and the Director of the University of North Carolina Institute for Drug Safety Sciences, discusses quantitative systems toxicology (QST) and quantitative systems pharmacology (QSP) modeling, recent examples of their application, and how they might better inform decision-making in the pharma industry. Dr. Watkins recently wrote a Commentary in PSP related to this topic and it is available here.

On today’s episode, Dr. Paul Watkins, the Howard Q. Ferguson Distinguished Professor at Eshelman School of Pharmacy, University of North Carolina at Chapel Hill and the Director of the University of North Carolina Institute for Drug Safety Sciences, discusses quantitative systems toxicology (QST) and quantitative systems pharmacology (QSP) modeling, recent examples of their application, and how they might better inform decision-making in the pharma industry. Dr. Watkins recently wrote a Commentary in PSP related to this topic and it is available here.

On this special joint episode of ClinPharmPod, the official podcast for Clinical Pharmacology and Therapeutics, and PSPod, the official podcast of CPT: Pharmacometrics and Systems Pharmacology Karthik Venkatakrishnan from Takeda Pharmaceuticals and Associate Editor for Clinical Pharmacology and Therapeutics, Lang Li, from the Ohio State University and Associate Editor for CPT: Pharmacometrics and Systems Pharmacology, and Valentina Shakhnovich from Children’s Mercy Hospital in Kansas City and Associate Editor for Clinical and Translational Science discuss reverse translation, the theme of a joint issue of articles recently published in the ASCPT journal family. They discuss the concept of reverse translation as a means to maximize the value of the ever-growing reservoir of real-world data in order to more effectively drive future research using retrospective analysis. Please visit the full joint virtual issue by clicking here.

On this special joint episode of ClinPharmPod, the official podcast for Clinical Pharmacology and Therapeutics, and PSPod, the official podcast of CPT: Pharmacometrics and Systems Pharmacology Karthik Venkatakrishnan from Takeda Pharmaceuticals and Associate Editor for Clinical Pharmacology and Therapeutics, Lang Li, from the Ohio State University and Associate Editor for CPT: Pharmacometrics and Systems Pharmacology, and Valentina Shakhnovich from Children’s Mercy Hospital in Kansas City and Associate Editor for Clinical and Translational Science discuss reverse translation, the theme of a joint issue of articles recently published in the ASCPT journal family. They discuss the concept of reverse translation as a means to maximize the value of the ever-growing reservoir of real-world data in order to more effectively drive future research using retrospective analysis. Please visit the full joint virtual issue by clicking here.

In this episode, Peter Bonate from Astellas, discusses effective communication in systems pharmacology and pharmacometric models. You can read a review of Dr. Bonate’s book Be a Model Communicator and Sell Your Models to Anyone, reviewed by Ellen Leinfuss in the May 2015 issue, by clicking here. Listen and subscribe for free on iTunes and Google Play

In this episode, Peter Bonate from Astellas, discusses effective communication in systems pharmacology and pharmacometric models. You can read a review of Dr. Bonate’s book Be a Model Communicator and Sell Your Models to Anyone, reviewed by Ellen Leinfuss in the May 2015 issue, by clicking here. Listen and subscribe for free on iTunes and Google Play

This episode features Sandra Visser and Anne Chain from Merck & Co/MSD, discussing existing practice and modeling approaches and some thoughts with regard to future directions for modeling to assess and predict cardiovascular liabilities of new drugs. You can read Dr. Visser’s Review “Implementation of Quantitative and Systems Pharmacology in Large Pharma” by clicking here. Listen and subscribe for free on iTunes and Google Play

This episode features Sandra Visser and Anne Chain from Merck & Co/MSD, discussing existing practice and modeling approaches and some thoughts with regard to future directions for modeling to assess and predict cardiovascular liabilities of new drugs. You can read Dr. Visser’s Review “Implementation of Quantitative and Systems Pharmacology in Large Pharma” by clicking here. Listen and subscribe for free on iTunes and Google Play

In this episode, we interview Dr. Shiew-Mei Huang, Deputy Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research at the Food and Drug Administration about a drug interaction database–a tool for evaluating the impact of renal or hepatic impairment in a pharmacologic inhibition on the systemic exposure of drugs. Read the article here. An Editorial describing the new Database article type can also be found here. Listen and subscribe for free on iTunes and Google Play

In this episode, we interview Dr. Shiew-Mei Huang, Deputy Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research at the Food and Drug Administration about a drug interaction database–a tool for evaluating the impact of renal or hepatic impairment in a pharmacologic inhibition on the systemic exposure of drugs. Read the article here. An Editorial describing the new Database article type can also be found here. Listen and subscribe for free on iTunes and Google Play

Matthias Machacek first studied mechanical engineering and graduated as PhD from ETH Zurich for his research on fluid dynamics and computer vision. He developed a visualization system for three-dimensional flows in wind tunnels, and his research applying computer vision to monitor molecules inside a live cell at nanometer scale was published in both Nature and Science.Today, Machacek applies engineering approaches in drug development, working in systems pharmacology and doing modeling for the development of biologics and cell based therapeutics. He is Managing Director of LYO-X and contributes to research in compound design, optimal format selection, competitive candidate selection, PK/PD and toxicology study design, first in human dose selection, optimal dose-regimen finding and pediatric development.Previously, Matthias established the Novartis Medical Engineering Group, dedicated to systems pharmacology support for the preclinical and translational development of biotherapeutics.

An-Dinh Nguyen interviews Avi Ma’ayan of Icahn School of Medicine at Mount Sinai on February 20, 2014. Dr. Ma’ayan will be a featured speaker during the shared session for the Systems Pharmacology and Cancer Informatics meetings at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the emergence of systems biology in drug research, promising datasets that can accelerate drug discovery and personalized medicine, methods for extracting knowledge from data, the potential research impact of systems pharmacology and more. Join Dr. Ma'ayan and a focused group of Systems Pharmacology Researchers at Bio-IT World 2014. Learn more about the program at http://www.Bio-ITWorldExpo.com/Systems-Pharmacology

An-Dinh Nguyen interviews Hugo Geerts of In Silico Biosciences and University of Pennsylvania on February 7, 2014. Dr. Geerts will be a speaker during the Systems Pharmacology conference at Bio-IT World Conference & Expo 2014, April 29-May 1 in Boston, MA. Topics include the limitations of translating outcomes from models for clinical utility, the application of computer-based methods to pharmaceutical R&D to improve predictability of clinical trials, the complexities of researching and developing drug therapies for the central nervous system and more.